7th Annual CAR-TCR Summit to Feature Presentation By Exacis Biotherapeutics CEO

Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will present “Leveraging mRNA Based Gene Editing to Optimize Advancement of Safe and Cost-Effective IPSC Products” as part of the focus track on Innovations in Gene Engineering and Editing at the 7^th Annual CAR-TCR Summit in Boston on September 19, 2022. As the leader of Exacis, Dr. Fiore has direct experience in the use of mRNA to reprogram somatic cells to iPSCs and using a proprietary mRNA-based gene editing platform to engineer the cells into NK and T cells for treatment of cancer.

“The advances we are making in genetic engineering for cell-based therapies are remarkable,” said Dr. Fiore. “Translating this research into developing off the shelf iPSC-derived cell therapies that are safe and effective will have a significant impact on the future of medical care.”

Topics covered in Dr. Fiore’s presentation will include:

• Engineering stealthing edits and performance enhancements to iPSCs with mRNA-based gene edited tools for enhanced persistence and potency
• Avoiding viral and DNA vectoring approaches and using a fusogenic lipid delivery system to transfect cells
• Expanding iPSCs during differentiation to yield large numbers of allogeneic NK cell therapies using an innovative and capital efficient manufacturing approach

The presentation will take place at 2:00 pm ET on Monday, September 19.

The 7^th Annual CAR-TCR Summit will be held September 19-22, 2022, in Boston, MA. The comprehensive forum focuses on the goal of engineering a disease-free world. Meeting attendees will explore discovery through to commercialization to deliver safe, effective, and commercially viable CAR and TCR therapies.

Exacis is a development stage immuno-oncology company focused on harnessing the human immune system to cure cancer by engineering next generation off-the-shelf NK and T cell therapies aimed at hematologic malignancies and solid tumors. Exacis was founded in 2020 with an exclusive global license to a broad suite of patents covering the use of mRNA based cell reprogramming and gene editing technologies for use in generating engineered NK and T cells for oncology applications.

Exacis’ approach avoids the use of DNA and viruses and instead uses a proprietary mRNA based technology. Exacis uses the technology to generate iPSCs and to edit their genome to create stealthed, performance enhanced allogeneic NK and T cell products, termed ExaNK™, ExaCAR-NK™ and ExaCAR-T™ cells.

T and NK cells are types of human immune cells that are able to recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.

Contact Exacis Biotherapeutics for further information and media: 

Exacis Biotherapeutics 

info@exacis.com